Glucotrack, Inc. GCTK
Glucotrack, Inc. (Nasdaq: GCTK) is a cardio-renal-metabolic medical device company. Its next catalyst on record is Glucotrack CBGM: Launch of US clinical program subject to FDA IDE approval (IDE submitted May 2026) (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Glucotrack CBGM — Launch of US clinical program subject to FDA IDE approval (IDE submitted May 2026) (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LT-100 (Lokahi Therapeutics; intradermal bee-venom-based toxin) | Knee osteoarthritis; multiple sclerosis | biologic-other | Phase 1 |
| Glucotrack CBGM | Type 1 / Type 2 diabetes glucose monitoring | — | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 22, 2026n/a Glucotrack, Inc. issued Senior Secured Convertible Promissory Notes and Warrants to investors under a Securities Purchase Agreement dated October 22, 2026.
This Warrant is the Warrant to purchase Common Stock (the "SPA Warrant") issued to Holder pursuant to that certain Securities Purchase Agreement dated October 22, 2026 by and between the Company and the Holder.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.